Hreat of fetal hypoxia carries dangers not only for the child but also for the woman giving birth as doctors often proceed quickly to a caesarean section if they feel there is a significant threat
Researchers at the University of Warwick have devised a new sensor which has the power to dramatically improve the amount of early warning doctors and midwives get of a dangerous situation in the birth process when the unborn child's brain is starved of oxygen - Fetal Hypoxia.
The threat of fetal hypoxia carries dangers not only for the child but also for the woman giving birth as doctors often proceed quickly to a caesarean section if they feel there is a significant threat of fetal hypoxia.
However current tests for this condition require blood samples to be taken to a lab for examination leading to delays which means doctors having to decide sometimes to proceed with a cesarean section rather than take the risk on waiting on that full analysis.
University of Warwick researcher Nick Dale had been looking at the science surrounding a chemical that can be found in blood called hypoxanthine.
An unborn child with more than 5 micromoles (five millionths of a mole) of hypoxanthine per litre of their blood is at severe risk of fetal hypoxia.
Dale was frustrated at the lack of effective instrumentation available to detect and study this chemical and devised his own fine tuned probe to examine the chemical.
On talking with colleagues in the University of Warwick's Medical School and University Hospitals Coventry and Warwickshire NHS Trust they pointed out that the probes would be of massive benefit to doctors in the delivery room.
Warwick Medical School researchers have examined the probes and say that the use of Professor Dale's probes to test for hypoxanthine would give doctors in delivery rooms almost instant data on whether the unborn child faced fetal hypoxia.
This would allow doctors to take more informed decisions as to whether to proceed to a caesarean section and probably therefore reduce the number of caesareans conducted.
Another advantage is that Dale's test also requires much less fine tuning than current tests (the blood PH test currently used to detect fetal hypoxia problems needs to identify a shift of as little of 0.05pH).
Dale is thrilled by the medical interest in his probes and is now working through a spin-out company Sarissa Biomedical - to take the work further.
Sarissa is already talking with a number of medical instrument manufacturers and aims to establish a partnership between Sarissa, a medical instrument manufacturer and venture capitalists to produce a full blown medical instrument using the new probes and then to take it to full clinical trials in hospital delivery rooms.
